Biopharma AI
ByIs Biopharma’s $8.5 Billion AI Investment in 2025 Across Discovery, R&D, and Commercialization Shaping the 2026 Innovation Landscape?
Global – December 31, 2025 — Biopharmaceutical companies significantly increased investment in artificial intelligence (AI) in 2025, allocating…
What Does SoftBank’s $41 Billion Bet on OpenAI Signal for the Future of Biopharma, Healthcare, and AI Infrastructure?
Global – December 2025 — SoftBank’s $41 billion investment in OpenAI represents one of the most consequential capital…
How Did Merck’s 2025 Deals Strengthen Its Pipeline and What Could They Mean for Future Growth?
In 2025, Merck pursued a series of high-impact collaborations, acquisitions, and licensing agreements to expand its portfolio, enhance…
Did Merck’s 2025 Strategies, Deals, and Pipeline Strength Position It for Breakthrough Growth in 2026?
Merck concluded 2025 with a strong performance across its pharmaceuticals, vaccines, and oncology segments, demonstrating resilience, strategic focus,…
Can Standigm’s Knowledge-Graph AI Outperform AI Peers Like Exscientia and Insilico as Global Pharma Commits $500M+ to Collaborative Discovery?
Strategic Overview Standigm is emerging as a distinctive force in AI-driven drug discovery by grounding its platform in…
Is Theremia Using AI to Unlock Next-Generation Immuno-Oncology Therapies and Advance Pharma Partnerships?
Strategic Overview Theremia is emerging as a pioneering AI-driven biotech focused on immune system modulation for oncology, integrating…
